Does treatment of newly diagnosed idiopathic thromboctypenic purpura reduce morbidity?

Treutiger, Iris; Rajantie, Jukka; Zeller, Bernward; Henter, Jan-Inge; Elinder, Göron; Rosthøj, Steen
August 2007
Archives of Disease in Childhood;Aug2007, Vol. 92 Issue 8, p704
Academic Journal
Aim: To explore whether early treatment of children with idiopathic thrombocytopenic purpura (IIP) with immunoglobulin and/or corticosteroids reduces subsequent morbidity. Methods: Centres participating in a Nordic lip study were divided according to whether they had treated more than 2/3, from 1/3 to 2/3, or less than 1/3 children within 14 days of diagnosis. The course of disease from 15 days to 6 months after diagnosis was compared for children managed at the three centre categories. The comparison was restricted to children in whom at least one platelet count <20×109/l was measured, numbering 156, 143 and 84 in the three different categories, respectively. Results: The three groups of children were clinically similar but were managed with initial treatment rates of 89%, 57% and 14%, respectively. By day 15, the platelet count had stabilised to >20 × 109/l in 67%, 67% and 52% (p<0.05) and to >150 × 109/l in 38%, 29% and 29% (p<020). At 1 month after diagnosis there was no difference in recovery rates. Chronic ITP developed in 27%, 22% and 25% in the three groups. During follow-up, one or more disease-related events occurred in 23%, 22% and 19%, with no difference in the average numbers of episodes with mucosal bleeding. Treatment courses were administered to 19%, 13% and 11%, respectively. Conclusion: Active treatment policies accelerated platelet recovery in children with short-lasting ITP but did not avert the development of chronic ITP and did not cause a reduction in morbidity during follow-up.


Related Articles

  • Management of Immune Thrombocytopenic Purpura in Adults. Stasi, Roberto; Provan, Drew // Mayo Clinic Proceedings;Apr2004, Vol. 79 Issue 4, p504 

    Primary immune thrombocytopenic purpura (ITP), also referred to as idiopathic thrombocytopenic purpura, is an organ-specific autoimmune disorder in which antibodycoated or immune complex-coated platelets are destroyed prematurely by the reticuloendothelial system, resulting in peripheral blood...

  • Idiopathic thrombocytopenic purpura in children. Roganović, Jelena // Acta Medica Academica;2009, Vol. 38 Issue 1, p21 

    Idiopathic thrombocytopenic purpura (ITP) is the most common acquired bleeding disorder in childhood. ITP is characterized by a low circulating platelet count caused principally by destruction of antibody-coated platelets in the reticuloendothelial system. It can be classified into two major...

  • Idiopathic thrombocytopenic purpura: a case of particular historic interest. Bannister, B. A.; Wonke, B.; Clendinnen, B. G. // Journal of the Royal Society of Medicine;Nov1980, Vol. 73 Issue 11, p828 

    The article cites a case of a five years old girl who was diagnosed of idiopathic thrombocytopenic purpura. The girl exhibited bruising and during medical examination, the patient had severe haematemesis, epistaxis and melaena with enlarged spleen and purpuric rash. The patient undergone...

  • An Update on Immune-Mediated Thrombocytopenia. Mitra Taghizadeh // Laboratory Medicine;Jan2008, Vol. 39 Issue 1, p51 

    Immune mediated thrombocytopenia is caused by autoantibodies or alloantibodies. Auto-antibody-related immune thrombocytopenic purpura (ITP) is the most common cause of immune thrombocytopenia. In the United States, 33,000 new cases of ITP are reported each year.1 Immune thrombocytopenic purpura...

  • Corticosteroid Resistant Idiopathic Thrombocytopenic purpura: Case report and literature review. Aziz, Fahad; Riaz, Jehanzeb // Internet Journal of Hematology;2009, Vol. 6 Issue 2, p1 

    Idiopathic thrombocytopenia purpura (ITP), also known as immune thrombocytopenic purpura, is defined as isolated thrombocytopenia with normal bone marrow aspirate and the absence of other causes of thrombocytopenia. The first line of treatment of ITP is corticosteroids. We present a case of a...

  • Novel treatment for Crohn's found to be more effective. Tanday, Sanjay // GP: General Practitioner;2/29/2008, p6 

    The article reports that a safe and effective ways of treating Crohn's disease has been developed which could eradicate the need for harmful steroids. Presently, corticosteroids is used to treat Crohn's disease to control the patients symptoms before immune-suppressing drugs to prepare the body...

  • Willebrand factor in von Willebrand's disease.  // British Medical Journal;11/15/1975, Vol. 4 Issue 5993, p384 

    Evaluates the risk factors of von Willebrand's diseases. Complication of disease due to prolonged bleeding and reduced plasma clotting factors; Identification of reduced antigenic factors VIII and diminished glass-induced adhesion and ristocetin induced aggregation of plasma; Classification of...

  • Chapter 16: Quantitative and Qualitative Platelet Disorders. Ciesla, Betty // Hematology in Practice;2007, p245 

    Chapter 16 of the book "Hematology in Practice" is presented. It focuses on quantitative and qualitative platelet disorders. It discusses the pathophysiology of various quantitative platelet disorders such as thrombocytopenia related to decreased production and thrombocytopenia related to the...

  • Thrombocytosis as a Predictor of Serious Bacterial Infection. MARWAHA, NEELAM // Indian Pediatrics;Nov2010, Vol. 47 Issue 11, p923 

    The author comments on a study which estimated the incidence of reactive thrombocytosis among febrile infants and assessed the utility of platelet count as a potential predictor of serious bacterial infection (SBI). She believes the study has provided valuable data where addition of a routine...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics